Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 1-Year High – Still a Buy?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)’s stock price hit a new 52-week high during trading on Tuesday . The company traded as high as $68.99 and last traded at $72.8550, with a volume of 13010 shares traded. The stock had previously closed at $63.53.

Key Kiniksa Pharmaceuticals International News

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Higher 2026 outlook: Kiniksa raised expected 2026 net product revenue to $980 million-$995 million, above the roughly $940 million analyst consensus. The revised outlook reflects continued momentum for ARCALYST (rilonacept). Kiniksa Pharmaceuticals Q2 2026 Results
• Positive Sentiment: Strong ARCALYST sales: Second-quarter net product revenue reached $243.6 million, approximately 55% higher year over year and well above the $226.5 million consensus estimate. EPS of $0.30 matched expectations and increased from $0.23 a year earlier. Kiniksa Q2 Earnings
• Positive Sentiment: Pipeline advances: KPL-387 Phase 2 results showed rapid, sustained reductions in pain and inflammation at the 300 mg monthly dose, which was selected for Phase 3. The pivotal recurrent-pericarditis study is now enrolling and dosing patients, adding a potential future growth driver. Kiniksa Portfolio Execution
• Positive Sentiment: Analyst support: JPMorgan raised its target to $107 and maintained an overweight rating; Canaccord raised its target to $98 with a buy rating; Wedbush raised its target to $99 with an outperform rating; and Citi raised its target to $100 with a buy rating. The revisions signal greater confidence in ARCALYST’s growth and Kiniksa’s pipeline.
• Neutral Sentiment: KNSA is trading near its 52-week high after a sharp rally, with a reported P/E ratio near 90. This reflects strong investor expectations and leaves the stock more sensitive to clinical setbacks, sales-growth deceleration or guidance misses.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Canaccord Genuity Group upped their price target on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research report on Wednesday. Weiss Ratings downgraded Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 23rd. The Goldman Sachs Group boosted their target price on Kiniksa Pharmaceuticals International from $60.00 to $75.00 and gave the company a “buy” rating in a research note on Thursday, July 23rd. Zacks Research upgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Wednesday, June 17th. Finally, JPMorgan Chase & Co. raised their price target on Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an “overweight” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $85.50.

Kiniksa Pharmaceuticals International Trading Up 2.0%

The stock’s fifty day moving average is $58.13 and its 200 day moving average is $50.71. The company has a market capitalization of $6.23 billion, a P/E ratio of 83.54 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 14.16%. The business had revenue of $243.60 million for the quarter, compared to analyst estimates of $226.49 million. On average, analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.25 EPS for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, CEO Sanj K. Patel sold 48,565 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $54.02, for a total transaction of $2,623,481.30. Following the completion of the sale, the chief executive officer directly owned 48,565 shares in the company, valued at approximately $2,623,481.30. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 58,424 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $53.71, for a total value of $3,137,953.04. Following the completion of the sale, the insider directly owned 65,623 shares in the company, valued at $3,524,611.33. The trade was a 47.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 51.98% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of large investors have recently made changes to their positions in KNSA. EverSource Wealth Advisors LLC boosted its holdings in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after acquiring an additional 532 shares in the last quarter. Osaic Holdings Inc. purchased a new stake in Kiniksa Pharmaceuticals International in the second quarter worth about $31,000. KBC Group NV bought a new stake in Kiniksa Pharmaceuticals International during the 1st quarter valued at approximately $34,000. Smartleaf Asset Management LLC bought a new stake in Kiniksa Pharmaceuticals International during the 4th quarter valued at approximately $36,000. Finally, Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter worth approximately $41,000. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.